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The relation between time to first shock and clinical out-
come was studied in 60 patients who received an auto-
matic implantable cardioverter-defibrillator (AICD) from
August 1983 through May 1988. The mean (±SD) pa-
tient age was 64 ± 10 years, 8 % were men and the
mean ejection fraction was 33 ± 13% . During follow-up,
38 patients (63%) had one or more shocks ; there were
no differences in age, gender distribution or ejection
fraction at entry between the shock and no shock
groups. Among 51 patients with coronary artery disease,
31 (61%) had one or more shocks, whereas all
seven patients with cardiomyopathy had one or more
shocks (p < 0 .05) . Neither of the two patients with idio-
pathic ventricular fibrillation had shocks .
Of the 13 deaths, 1 occurred during post-hospital
follow-up and 1 during the index hospitalization . Of the
four sudden post-hospital deaths, only one was due to
tachyarrhythmia in the absence of acute myocardial infarc-
tion . All four sudden deaths and five of eight post-hospital
nonsudden deaths occurred in patients who had had one or
more appropriate shocks during follow-up . Eight of the
nine first appropriate shocks among patients who subse-
quently died occurred within the first 3 months of follow-
up, but the actual deaths were delayed to a mean of 14 .1 ±
13.9 months (p < 0.05). The mean time to all deaths was
14 .8 ± 13 .1 months. The ejection fraction was significantly
lower among patients who died than among patients who
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survived ( 5 ± 7% versus 35 ± 14%, p < 0.0 ), but it did
not distinguish risk of first shocks .
Among the 38 patients who had one or more shocks
during follow-up, 0 (53%) had their first shock within the
first months of follow-up and 9 (76%) by the 6th month .
By 1 year, 34 (89%) of the 38 had had one or more shocks ;
no patient had a first appropriate shock >16 months after
AICD implantation. Those patients who died of any cause
during follow-up had a shorter time to first shock ( .3 ± .0
months) than did those who continued as survivors (5 .5 ±
6.1 months) (p < 0 .05). After the occurrence of a first shock,
the mean total number of shocks was 11 .0 ± 17.9, but the
distribution was bimodal with 50% of the patients having no
additional shocks after the first one . The use of antiarrhyth-
mic drugs at discharge did not influence time to first shock .
It is concluded that the majority of patients who have
any shocks after AICD implantation tend to have their first
shock within the first few months after implantation, and
the risk for a first shock is low if it has not occurred within
the first 1 .5 years . Ejection fraction does not discriminate
risk of having shocks, but does discriminate risk of death
during follow-up . The AICD appears to prolong duration of
survival among those patients who will die during follow-
up, although the magnitude of prolonged survival and
impact on total death rate is less clear than is reduction of
arrhythmic sudden death .
(J Am Coll Cardiol 1989;14:508-14)
The automatic implantable cardioverter-defibrillator (AICD)
was developed as an interventional device for patients at
high risk for lethal arrhythmias (1), when pharmacologic or
surgical therapy is considered unreliable . Clinical trials and
subsequent widespread clinical use ( -6) have established
the efficacy of the device for achieving the goal of sensing
and automatically converting ventricular fibrillation and
rapid sustained ventricular tachycardia . Among the negative
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factors associated with its use are the need for frequent
follow-up evaluations and generator replacements, cost,
surgical complications, drug interactions and psychologic
impact on the patients . Previous reports (3-5,7,8) have
provided impressive information on long-term survival, as
well as comprehensive data on the complications and prob-
lems in long-term management of AICD patients . In this
report, the experience observed at the University of Miami
Medical Center is presented with particular emphasis on an
analysis of the time interval between implantation and the
first shock, mechanisms of death in nonsurvivors and dis-
tinctions between clinical outcome in patients who have any
shocks versus that in patients who have none .
Methods
Study patients . The study group includes 60 patients who
had their first AICD unit implanted at the University of
Miami/Jackson Memorial Medical Center and the Miami
Veterans Administration Medical Center from August 1983
through May 1988 . Eighty-two percent of the patients (49 of
60) were tertiary referrals after survival from out of hospital
cardiac arrest or recurrent sustained ventricular tachycardia .
The remaining 18% were primary entrants through the
emergency room of our hospitals after having had sustained
ventricular tachycardia or ventricular fibrillation responded
to in the community by emergency rescue services . The
criteria for AICD implantation were 1) recurrent cardiac
arrest or recurrent symptomatic sustained ventricular tachy-
cardia on a drug regimen that had been predicted to be
successful by prior programmed electrical stimulation stud-
ies ; ) failure of more than two drugs or drug combinations,
or of antiarrhythmic surgery, to prevent inducible arrhyth-
mias after documented clinical ventricular tachycardias as-
sociated with cardiovascular collapse or after ventricular
fibrillation ; or 3) out of hospital cardiac arrest with clinical
markers for high risk of recurrence even if noninducible by
programmed stimulation studies . Patients in whom ventric-
ular tachycardia or fibrillation occurred only in the acute
phase of myocardial infarction were not AICD candidates .
Patient evaluation . Thorough diagnostic evaluation was
performed on all patients to establish an anatomic and
electrophysiologic diagnosis. Data from cardiac catheteriza-
tion and coronary angiography were provided from studies
at our institution or from the referring institution . Pro-
grammed electrical stimulation studies to determine or doc-
ument the entry criteria outlined were performed in all
patients . Four patients whose tachyarrhythmia was not
inducible at baseline study were determined to be AICD
candidates on clinical grounds because of high risk . The
cumulative data available permitted 1) the identification of
the dominant underlying etiologic diagnosis in all patients ; )
an electrophysiologic profile based on programmed stimula-
tion study in all except the four without inducible arrhyth-
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mia; and 3) an assessment of left ventricular function as
measured by an ejection fraction at the time of AICD
implantation in all but one patient. The baseline variables
used in analysis of outcome data were age, gender, etiologic
diagnosis, ejection fraction at time of AICD implantation,
unsuccessful antiarrhythmic drugs before implantation and
antiarrhythmic drugs used from discharge to a first terminat-
ing event-e .g ., first shock or death .
Follow-up . From August 1983 to October 1986, all en-
trants were followed up in the Arrhythmia Clinic at the
University of Miami/Jackson Memorial Medical Center .
From then to the present, 14 of the surviving entrants have
been followed up independently by one of us (R.M.L .) . The
remaining entrants surviving to that date and the patients
who had an AICD implant after October 1986 have been
followed up at the Arrhythmia Clinic or at the Miami
Veterans Administration Medical Center, with the exception
of eight patients who were referred to other cardiologists
(four out of state, two out of county, two in Miami) able to
provide follow-up service for patients with an AICD unit .
Follow-up information for the latter is being obtained from
the cardiologists to whom the patients were referred .
Follow-up procedures included an initial visit I month
after implantation, bimonthly visits thereafter until 1 year
after implantation then monthly visits until the Elective
Replacement Indicator (ERI) charge time was reached, at
which point an elective replacement was scheduled . A
record of all symptoms attributable to arrhythmias, the
number of discharges counted by the units and any change in
clinical status was maintained for all patients . Appropriate
shocks were defined as those preceded by symptoms of a
ventricular arrhythmia or documentation by concurrent
monitoring, or both . Inappropriate shocks were defined as
those that occurred in the absence of symptoms or of
exercise, or were triggered by a supraventricular tachycar-
dia. All patients who had asymptomatic shocks subsequently
underwent ambulatory monitoring to attempt to determine
whether the shocks were inappropriate . Inappropriate
shocks were excluded from the analysis . Outcome variables
were first appropriate shock, sudden death and total mortal-
ity. Sudden death was defined conventionally as death
within 1 hour of onset of abrupt change in symptoms . For all
sudden deaths, further data were accumulated to distinguish
between tachyarrhythmic events and other mechanisms .
AICD implantation and replacement procedures. AICD
implantation was accomplished by standard techniques (9) .
Left thoracotomy or median sternotomy was used exclu-
sively for epicardial placement of patches, sensing leads and
pacing leads when necessary . Left thoracotomy was used in
17 patients in conjunction with transvenous superior vena
cava or bipolar sensing leads, or both; in 1 patient, it was
used for implantation of a totally epicardial system . Of these
18 patients, 7 had undergone open heart operations in the
remote past . In the other 4 patients, sternotomy was used .
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Table 1 . Subgroup Characteristics of 60 Patients With an Implanted AICD
Among six of these, some or all of the leads and patches
were placed at the time of an open heart procedure, and the
pulse generator was then implanted at a later date .
There was one in-hospital death ( %) after surgery for
AICD placement. The patient had an acute myocardial
infarction in the early postoperative period and died in
cardiogenic shock . Major morbidity occurred in four pa-
tients (7%) . In each, postoperative respiratory failure re-
quired prolonged ventilator support . Each of these patients
had recently received amiodarone, which was believed to
have contributed to the complication . No mortality or com-
plications were associated with replacement of generators .
Data collection and statistical analysis . Updated records
on the clinical status of the patients at the time of AICD
implantation, time to first appropriate shock and number of
subsequent shocks and sudden and total deaths were main-
tained in the files of the investigators. All deaths were
evaluated for mechanism (sudden : arrhythmic, nonarrhyth-
mic ; nonsudden : cardiac, noncardiac) (10) . Data were ana-
lyzed for shocks versus no shocks in relation to sudden and
nonsudden deaths and baseline clinical variables, including
use of antiarrhythmic drugs after AICD implantation . T tests
for differences between the means for unpaired data, and
paired t tests where appropriate, were applied to the various
subgroups . A chi square test using a
x
contingency table
was used where appropriate . Life table analysis was carried
out by the BMP:PIL software program (11), based on
Kaplan-Meier estimates . Values are expressed as mean
values ± SD .
Results
Clinical characteristics. Among the 60 patients included
in this report, 45 (75%) initially presented after surviving an
out of hospital cardiac arrest, and 15 ( 5%) had had recurrent
sustained ventricular tachycardia that was symptomatic be-
cause of hemodynamic compromise
. The group comprised
49 men (8 %) and 11 women ; the mean age at the time of
AICD implantation was 63.9 ± 9.6 years. The primary
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*Includes one postoperative death due to acute myocardial infarction after AICD implantation-see text
; tp < 0 .0 versus survivors . CAD = coronary artery
disease ; CM = cardiomyopathy ; EF = ejection fraction ; IVF = idiopathic ventricular fibrillation .
underlying etiology was coronary artery disease in 51 pa-
tients (85%), dilated cardiomyopathy in 7 (1 %) and idio-
pathic ventricular fibrillation in the absence of identifiable
structural or functional cardiac abnormalities in (3%) .
Table I lists selected demographic and clinical information
for the total group, for the subgroups of patients having "any
shocks" versus those having "no shocks" during follow-up
and for patients who died during follow-up (total deaths and
sudden deaths) . Documented inappropriate shocks (see
"Methods") were not counted, nor were shocks strongly
suspected to be inappropriate : 1) those without preceding
symptoms, and
) those occurring during exercise . All
suspected or documented inappropriate shocks occurred in
patients who also had appropriate shocks, with one excep-
tion of a patient who had lead failure causing documented
inappropriate shock .
Follow-up . There were no differences in the mean ages of
patients who had any appropriate shocks, no shocks, those
who died during follow-up or those who continued as survi-
vors (Table 1) . The male/female ratio for patients who died
was higher (1 of 13 ; 9 % male) than that for the survivors
(37 of 47 ; 79% male), but the difference did not achieve
statistical significance. There were no differences in male/
female distribution between the "any shock" and "no
shocks" subgroups . Thirty-one (61%) of 51 patients with
coronary artery disease had one or more shocks compared
with 100% of 7 patients with cardiomyopathy (p < 0 .05) .
Neither of the two patients with idiopathic ventricular fibril-
lation had had a shock by 36 and 4 months of follow-up,
respectively .
Ejection fraction
. There was no difference in ejection
fraction at the time of implantation between the subgroup
that subsequently had any shocks and those individuals who
had none (mean ± SD = 33 ± 13% versus 33 ± 14%, p =
NS). The mean ejection fraction (±SD) among all patients
who died was 5 ± 7%, significantly lower than that among
the continuing survivors (35 ± 14%) (p < 0 .0 ) . Ejection
fraction among patients who died suddenly during follow-up
Total Group Any Shocks
No Shocks Total Deaths Sudden Deaths
Patients (no.) 60*
38 (63%) (37%)* 13 ( %) * 4 (7%)
Age (yr) 63 .9 ± 9 .6 64 .8 ± 8 .9 6 .7 ± 10 .4 6 .8 ± 9 .6 63 . ± .1
Gender (male/female)
49/11 30/8 19/3 1 /1 4/0
(8 % male) (79% male) (86% male) (9 % male) (100% male)
Diagnosis
CAD 51 (85%) 31 (8 %) 0(91%) 1 (9 %) 4(100%)
CM 7 (1 %) 7 (18%)
1 (8%) -
IVF (3%) - (9%) - -
EF (%) 33 ± 13 33 ± 13 33±14 5±7t 0±5
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Table . Antiarrhythmic Drugs at Hospital Discharge in 59 AICD Patients
*Excludes one early postoperative death due to acute myocardial infarction ; tl patient received a class IA/IB drug combination ; fl patient received a class
IB/III drug combination
.
averaged 0 ± 5% (mean ± SD), but this was not subjected
to statistical analysis because of the small number .
Antiarrhythmic drugs . Categories of antiarrhythmic drugs
prescribed for AICD patients at the time of hospital discharge
after their first implantation are listed in Table . The decision
to use antiarrhythmic drugs was based on the frequency and
forms of ventricular arrhythmia on continuous ECG monitor-
ing before discharge and on the expected frequency of sus-
tained arrhythmias based on clinical and electrophysiologic
observations. Once selected, drugs were not changed before a
censoring event . Among the total group, 3 patients (39%)
were discharged on no antiarrhythmic drugs, 17 ( 9%) re-
ceived amiodarone and the remainder received the various
antiarrhythmic drugs shown in Table . There was no associ-
ation between the use and type of antiarrhythmic drugs and
the risk of shock . There were not enough deaths to evaluate
any possible impact of antiarrhythmic drugs .
Table 3. Analysis of Time to Events After Hospital Discharge in
59 Patients*
*One patient who died of acute myocardial infarction in the early
postoperative period after AICD implantation is excluded from this analysis-
see text ; tp < 0 .01 ; tp < 0 .05 . F/U = follow-up
.
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AICD discharges, sudden deaths and all cause mortality
during follow-up (Table 3). Based on a follow-up cutoff date
of December 31, 1988, the mean time to last follow-up for
entrants who continued as survivors as of the cutoff date was
5 months (median 3 months, range 7 to 64). One patient
had an AICD explanted because of pocket erosion, had had
no shocks and was censored out of the study at the time of
explantation ( 5 months) . When the data were analyzed from
the time of implantation to last follow-up, including the time
to fatal events for those who died during follow-up, the mean
duration of follow-up was 4 months (median mont' s,
range 1 to 64) .
Thirteen patients died after receiving an AICD, four of
them suddenly . However, only one sudden death appears to
have been a true tachyarrhythmic event not associated with
another acute cardiac mechanism ; it occurred at 10 months
of follow-up in a patient who had had a first symptomatic
AICD shock at 1 month . Two additional sudden deaths
occurred during the 4th week after implantation in patients
who had had prior post-hospital shocks . One of these two
patients was found at autopsy to have an acute thrombus
superimposed on an atherosclerotic plaque in a vein graft to
the left anterior descending coronary artery, causing a large
acute anteroseptal myocardial infarction . His AICD power
supply was depleted, but the unit functioned properly with
an external power source, suggesting that he had had many
discharges during the terminal event . The other patient had
had end-stage heart disease with a 15% ejection fraction and
died in electromechanical dissociation documented by emer-
gency rescue service recordings . The fourth sudden death
occurred at 10 months of follow-up in a patient who had had
his first shock at 7 months . He had recently developed heart
failure and died during an episode of acute decompensation .
He did not have an AICD discharge during the terminal
event (documented by a postmortem AICD pulse count) .
The remaining nine deaths were nonsudden ; seven
of
these were cardiac and two noncardiac . One nonsudden
cardiac death occurred during surgery in a patient who had
Total Group*
(n = 59)
Any Shocks
(n = 38)
No Shocks*
(n = 1)
Total Deaths*
(n = 1 )
Sudden Deaths
(n = 4)
No drugs 3 (39%) 160 %) 7 (3317c) 3 ( 5%) (50%)
Class IA 8 (14%)t 4 (11%)t 4(19%) (17%)t
0(-)
Class IB 7 (1
%)tt 5 (13%)tt
(10%) (l7%)t 1 ( 5%)
Class IC 1 ( %) 1 (3%) 0(-)
0( - )
0 (-(
Class II 3 (5%) 1 (3%) (10%) 1 (8%)
0( - )
Class III
Amiodarone 17 ( 9%) 11 ( 9%) 6( 9%) 5 (4 %) 1 ( 5%)
Sotolol
(3%)t (5%)t
0(-) 0(-)
0( - )
Months
Duration of follow-up to last evaluation or death
Mean, median, range for survivors 5 . 3, 7 to 64
Mean, median, range with censoring for fatal 4, , t to 64
events
Time to first shock (mean ± SDI
Among all patients having shocks (n = 38) 4.4 ± 5 .6
Among surviving patients (n = 9)
5 .5 ± 6 . It
With death during F/U (n = 9) .3 ± .Ot
Time to death
Among all deaths* (n =
1
)
14 .8 ± 13 .1
Deaths with any prior shocks (n = 9)
14 .1 ± 13 .9
Deaths with no prior shocks (n = 3) 16 .7 ± 11 .5
Among patients with any shocks and death during
subsequent follow-up
Time to first shock .3 ± .0
Time to death
14 .1 ± 13 .91
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Figure 1 . Distribution of time intervals to first shock . The time
interval from implantation of the automatic implantable cardio-
verter/defibrillator (AICD) to the first shock during follow-up (F/U)
is displayed for the 38 of 59 patients who entered post-hospital
follow-up and have had one or more AICD shocks (see text for
details) .
end-stage cardiomyopathy, and three during the course of a
new acute myocardial infarction. Another occurred as a
result of an acute myocardial infarction during the early
postoperative period after AICD implantation . This event
was included in the analysis of total mortality experience,
but not in the analysis of post-hospitalization AICD shocks
and mortality experience .
The 13 sudden and nonsudden deaths represent a %
total mortality rate among the 60 patients . The 1 deaths
during post-hospitalization follow-up occurred at a mean
interval of 15 months after implantation (median 10 months,
range of 1 to 35) . Nine (75%) of the patients who died during
follow-up had had prior AICD shocks . All four of the
patients whose death was classified as sudden during post-
hospital follow-up had had prior shocks, as had five of the
eight patients whose death was classified as nonsudden .
Three of the first shocks in the four patients who died
suddenly occurred during the 1st month of follow-up ; the
fourth patient had a first shock at 7 months of follow-up . The
first shock in the five patients who died nonsuddenly oc-
curred within the 1st 3 months of follow-up (in the 1st month
in one patient and in the nd and 3rd months in two each)
(Fig . 1). Therefore, among all patients with a prior shock
who died, only one had a first shock that occurred later than
the 3rd month of follow-up .
Time to first shock and subsequent course . Thirty-eight
(64%) of the 59 patients who entered post-hospital follow-up
had one or more shocks . The AICD shock experience is
stratified according to underlying etiology in Table 1 . In
addition, Figure 1 demonstrates that, of the 38 patients who
had any shocks, 14 (37%) had their first shock within the 1st
month and 0 (53%) within the l st months of follow-up .
The first shock occurred in 9 (76%) of the 38 patients by the
6th month of follow-up and in 34 (89%) by the end of the 1st
'
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year. The first shock occurred in one patient at 14 months, in
one at 15 months and in two at 16 months .
After having a first shock, the group was prone to have
multiple shocks, although a bimodal pattern emerged over
time (see later) . The mean total number of shocks delivered
to the group of patients who had any shocks (excluding
inappropriate shocks) was 11 .0 ± 17 .9 (range 1 to 67) .
However, only 1 of the 38 patients (55%) had more than one
shock. The patients who had shocks and subsequently died
are included in this analysis ; five of the nine had had only
one shock before their fatal event . It was not possible to
distinguish those patients who would have only one shock
from those at risk for multiple shocks on the basis of age,
diagnosis, ejection fraction or antiarrhythmic drug use . In
this series, the latest shock occurred at 38 months in a
patient who had his first shock at 1 month and a total of 63
appropriate shocks .
Ejection fraction. There was no correlation between
ejection fraction at the time of surgery for AICD implanta-
tion and time to first shock . Among patients who had a first
shock within months of surgery, the ejection fraction was
3 ± 14%. For those with a first shock in the 3rd or 4th
month, the ejection fraction was 30 ± 13% ; and for the 5 to
8 month group, it was 9 ± 8% . For the six patients whose
first shock occurred after the 8 month, the mean ejection
fraction was 41 ± 14% .
Antiarrhythmic drugs . Among the 38 patients who have
had one or more shocks, 16 (4 %) were discharged receiving
no antiarrhythmic drugs and (58%) did receive antiarrhyth-
mic drugs at discharge . The mean time to first shock was 4 .0
± 3.8 months among those discharged without antiarrhyth-
mic drug therapy and 5 .3 ± 6.6 months among those dis-
charged with such therapy (p = NS) . The 11 patients
discharged on amiodarone therapy had a mean time to first
shock of 5 .4 ± 6.1 months ; those discharged on treatment
with all other antiarrhythmic drugs or combinations had a
time to first shock of 5 .3 ± 7.5 months .
Survival : life table analysis . Life table analysis for sudden
deaths, total deaths and time to first shock (potential deaths)
is demonstrated in Figure . The 1 year actuarial sudden
death rate was 9%, and total death rate at 1 and years was
14% and 17%, respectively. Life table analysis of risk of first
appropriate shock, or "potential death," demonstrated a
34% risk at months, 49% at 6 months, 60% at 1 year and
67% at 16 months. Of the 59 posthospital patients who
entered the 1st year of follow-up, 35 (59%) had a censoring
event during the 1st year (i .e ., first appropriate shock or
death without a prior shock) . Sixteen patients were alive and
free of a first shock at the beginning of the nd year of
follow-up, five of whom (31%) had a censoring event during
the nd year . One of the eight patients entering the 3rd year
of follow-up event-free had an event during the 3rd year-a
nonsudden death at 8 months .
The mean time to first shock among all 38 patients who
have had shocks was 4.4 ± 5 .6 months, and among the 9
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Figure . Life table analysis of sudden death, total death and time to
first shock during follow-up . Probability of remaining free of sudden
death (dotted line), total death (dashed line) and a first shock with
survival (solid line) is demonstrated with use of Kaplan-Meier
estimates (see text for details) .
continuing survivors who had any shocks was 5 .5 ± 6 .1
months (Table 3) . The time to first shock among the nine
patients who died during follow-up was .3 ± .1 months
(p < 0
.05 versus survivors). The time to death was 14
.8 ±
13.1 months among all 1 patients who died during post-
hospitalization follow-up and 14 .1 ± 13 .9 months among the
9 who had had more than one shock before death . Among
patients who subsequently died after having had more than
one shock, the interval between the first shock (i .e ., poten-
tial death) and actual death was significant (p < 0 .05),
suggesting that the AICD did prolong life (Table 3) in the
subgroup of patients who ultimately died . This analysis was
based on first-shock events documented to be appropriate or
associated with symptoms indicating an appropriate shock .
On the basis of an intention to treat analysis, in which time
to first shock was compared with time to all deaths (whether
or not shocks occurred before death), the group differences
between the mean time to first shocks and time to all deaths
was greater (1
.5 months, p < 0 .001) .
Discussion
Predictive role of early AICD shock during follow-up .
AICD discharge experience within the first 18 months of
follow-up after implantation appears to be predictive of
future events . Seventy-six percent of our patients who had
any shocks during follow-up had had one or more shocks
within the first 6 months, and no patient has experienced an
appropriate first shock after 16 months of follow-up
. Griffith
et al . (1
) reported a similar experience, demonstrating that
83 (95%) of 87 patients who had had either an AICD shock or
an arrhythmic death during follow-up had had a first shock
within 4 months ; 79 (90%) of these events had occurred by
the 18th month . A short time from implantation to first shock
was suggestive of increased risk of future deaths in our
patients . Nine of 1 patients who died during post-hospital
follow-up had appropriate AICD discharges before the fatal
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event, and eight of these nine patients had had their first
shock within the first 3 months of follow-up (mean
.3 t .1
months)
. Their actual fatal events occurred 14 .1 ± 13 .9
months after implantation . Three of the four patients who
died suddenly during follow-up had a first shock in the first
month of follow-up . It is noteworthy that, although only 31
(61%) of 51 patients with coronary artery disease had any
shocks during follow-up, all but one of the deaths during
follow-up occurred in this subgroup. In contrast, all seven
patients with cardiomyopathy had one or more shocks, but
only one of these seven patients died .
Incidence of sudden death . The overall 7% incidence rate
of sudden death is high compared with that in other reports
of AICD experience (3) . However, we used the conventional
definition of sudden cardiac death (see "Methods"), which
does not distinguish tachyarrhythmic sudden deaths from
other mechanisms (13) . In unselected populations, 70% to
90% of such events are ventricular tachycardia/fibrillation,
but in this study only one of the four sudden deaths met
criteria for a ventricular tachycardia/fibrillation death in the
absence of an acute myocardial infarction. This fact reflects
the efficacy of the AICD in preventing tachyarrhythmic
deaths, thus increasing the proportion of nonarrhythmic
deaths . One of the other three patients who died suddenly,
died in electromechanic dissociation, another had a massive
acute myocardial infarction and the third died in acute heart
failure without an arrhythmia . Therefore, our 7% sudden
death rate does not reflect a true incidence of sudden
tachyarrhythmic deaths in patients with an AICD because
sudden deaths in AICD patients frequently occur by mech-
anisms other than ventricular tachycardia/fibrillation .
Impact of AICD on total mortality .
Although there are
strong data indicating that arrhythmic sudden cardiac deaths
in high risk patients are decreased by the AICD
(1-6), the
impact on total mortality is not as clear . Reduction of total
mortality is a necessary measure of efficacy, but it does not
appear to be reduced in proportion to the reduction in
expected arrhythmic deaths in our high risk population. Two
of the largest early reports ( ,3) on AICD efficacy demon-
strated differences in both sudden and total death rates .
However, from the data provided in the two reports, the
patient populations differed in extent of disease as reflected
by differences in mean ejection fractions . In the study
comprising patients having lower ejection fractions
( ), the
total mortality was higher
. Among our patients who died
during follow-up, the ejection fraction was significantly
lower (mean 5%) than that among survivors (mean 35%, p
< 0.05), and this difference was independent of whether or
not they had had prior shocks
. There was no significant
correlation between ejection fraction at the time of implan-
tation and time to first shock
. Therefore, ejection fraction
data did not discriminate risk of having shocks but did
indicate risk of subsequent death among patients who had
had shocks .
When we compared time to events for first shocks and for
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deaths, we observed that survival time was prolonged by
approximately 1 year when time to death was indexed to
time to first shock ("aborted death") for those patients who
had one or more appropriate shocks and later died . When
time to all deaths, including death in patients who had not
had preceding shocks, was indexed to time to first shocks
(intention to treat analysis), calculated prolongation of sur-
vival was lengthened and significance of the differences was
greater. Therefore, even if total mortality rates are influ-
enced only partly by the AICD, the AICD appears to have a
significant influence on duration of survival .
Role of amiodarone and other antiarrhythmic drugs. The
use of amiodarone before AICD surgery appeared to influ-
ence the postoperative course . All four of our nonfatal major
surgical complications occurred in patients who had been
receiving amiodarone before surgery . In all four, postoper-
ative respiratory failure, due to respiratory distress syn-
drome, required long-term respiratory support, lasting 4
weeks in one . All patients survived, but this association
raises questions about amiodarone trials in potential
AICD
candidates
.
The use of antiarrhythmic therapy after AICD implanta-
tion
did not influence risk of having more than one shock
among our patients ; but, in the absence of randomization, it
is impossible to determine whether selection bias influenced
shock experience . Higher risk might influence decisions
about the use of antiarrhythmic drugs by the patients'
primary physicians . However, there were no drug changes
between implantation and first shocks
; drug changes were
made after multiple shocks in attempts to limit the number of
shocks. The time to first shock was 5
.4 ± 6 .1 months among
the 11 patients receiving amiodarone and 5
.3 ± 7.5 months
among 9 patients receiving any other antiarrhythmic drug or
drug combination
. The 15 patients receiving no antiarrhyth-
mic drug had a similar time to first shock (4 .0 ± 3 .8 months) .
The numbers for individual drugs other than amiodarone
were too small to analyze risk of shock or time to first shock .
No attempt was made to control for changes in antiarrhyth-
mic therapy after discharge from the initial hospitalization .
Clinical implications . It is not yet possible to draw con-
clusions on the clinical application of data on the low risk of
having a late event among patients who have remained free
of a first shock for 18 to 4 months after AICD implantation .
Only 1 of our patients have entered the 19th month of
follow-up free of a censoring event . Nonetheless, observa-
tions in patients who have major cardiovascular events-
e.g., acute myocardial infarction, new onset angina pectoris,
out of hospital cardiac arrest-suggest that recurrences or
other major cardiovascular events in high risk subgroups
tend to cluster within the first 4 months after the index
event
. Beyond that time, the excess rate of new or recurrent
events falls toward the risk of the underlying disease,
unmodified by the index event .
A large multicenter study would be necessary to deter-
mine whether the risk to patients who have an
AICD is low
enough to consider not replacing an AICD generator after
>_
4 months free of any AICD discharges. If a subgroup of
patients can be identified that does not require a lifetime
commitment to the AICD, the criteria for initial implantation
might be relaxed, limiting long-term commitments to those at
high risk for multiple shocks . Post facto identification of
individual patients who remain at high risk for recurrent
events, and their distinction from those who are at low risk,
could yield a highly specific population of patients in need of
the AICD . Even if the data become available, however, the
decision to apply the principle of selective generator replace-
ment will not come easily because of uncertainty about
clinical, legal, philosophical and epidemiologic issues . These
are issues that await future clarification .
We are grateful to Thelma L
. Gottlieb for administrative and secretarial
support .
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